Search results
Results from the WOW.Com Content Network
The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas. The term " induction regimen " refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer ...
Gemcitabine treats various carcinomas.It is used as a first-line treatment alone for pancreatic cancer, and in combination with cisplatin for advanced or metastatic bladder cancer and advanced or metastatic non-small cell lung cancer.
In combination with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer (BTC). [ 13 ] In June 2024, the US FDA approved durvalumab with carboplatin plus paclitaxel , followed by single-agent durvalumab, for adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
Toripalimab is indicated in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. [ 1 ] [ 5 ] It is also indicated as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or ...
Cisplatin, a platinum-based chemotherapeutic and radio sensitizer. A radiosensitizer is an agent that makes tumor cells more sensitive to radiation therapy. It is sometimes also known as a radiation sensitizer or radio-enhancer.
In early stage one small cell lung carcinoma, adjuvant chemotherapy with gemcitabine, cisplatin, paclitaxel, docetaxel, and other chemotherapeutic agents, and adjuvant radiotherapy is administered to either the lung, to prevent a local recurrence, or the brain to prevent metastases.
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). [ 5 ] [ 6 ] [ 3 ] It was counterproductive in non-squamous non-small-cell lung carcinoma.